PT - JOURNAL ARTICLE AU - Solastie, Anna AU - Virta, Camilla AU - Haveri, Anu AU - Ekström, Nina AU - Kantele, Anu AU - Miettinen, Simo AU - Lempainen, Johanna AU - Jalkanen, Pinja AU - Kakkola, Laura AU - Dub, Timothée AU - Julkunen, Ilkka AU - Melin, Merit TI - A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA and IgM class antibodies AID - 10.1101/2021.07.28.21260990 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.28.21260990 4099 - http://medrxiv.org/content/early/2021/07/30/2021.07.28.21260990.short 4100 - http://medrxiv.org/content/early/2021/07/30/2021.07.28.21260990.full AB - Background Validation and standardization of accurate serological assays are crucial for the surveillance of the coronavirus disease 2019 (COVID-19) pandemic and population immunity.Methods We describe the analytical and clinical performance of an in-house fluorescent multiplex immunoassay (FMIA) for simultaneous quantification of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein and spike glycoprotein. Furthermore, we calibrated IgG-FMIA against World Health Organisation (WHO) International Standard and compared FMIA results to an in-house enzyme immunoassay (EIA) and a microneutralisation test (MNT). We also compared the MNT results of two laboratories.Results IgG-FMIA displayed 100% specificity and sensitivity for samples collected 13-150 days post-onset of symptoms (DPO). For IgA- and IgM-FMIA 100% specificity and sensitivity were obtained for a shorter time window (13-36 and 13-28 DPO for IgA- and IgM-FMIA, respectively). FMIA and EIA results displayed moderate to strong correlation, but FMIA was overall more specific and sensitive. IgG-FMIA identified 100% of samples with neutralising antibodies (NAbs). Anti-spike IgG concentrations correlated strongly (ρ=0.77-0.84, P<2.2×10−16) with NAb titers. The NAb titers of the two laboratories displayed a very strong correlation (ρ=0.95, P<2.2×10−16).Discussion Our results indicate good correlation and concordance of antibody concentrations measured with different types of in-house SARS-CoV-2 antibody assays. Calibration against WHO international standard did not, however, improve the comparability of FMIA and EIA results.Competing Interest StatementNE, CV and MM are co-investigators in an unrelated study, for which THL has received research funding from GlaxoSmithKline Vaccines. AS, AH, AK, SM, JL, PJ, LK, TD and IJ report no conflicts of interest.Funding StatementThe study was supported by funds from the Finnish Institute for Health and Welfare, University of Turku and the Academy of Finland (grant numbers 336439, 336431, 337527, 335527 and 335530), the Finnish Medical Foundation, the Finnish governmental subsidy for health science research and Jane and Aatos Erkko Foundation (grant number 5360-cc2fc).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The investigations were carried out under the General Data Protection Regulation (Regulation (EU) 2016/679, directive 95/46/EC) and the Finnish Personal Data Act (Finlex 523/1999). The study protocols for the collection of pre-COVID-19 pandemic samples and COVID-19 patient samples were approved by the Helsinki-Uusimaa health district ethical permissions 433/13/03/00/15 and HUS/1238/2020.The Finnish law on communicable diseases and the duties of the Finnish Institute for Health and Welfare [20,21] allowed the implementation of the initial household transmission study without seeking further institutional ethical review.A waiver of ethical approval was received from Prof. Mika Salminen, director of the Department for Health Security of the Finnish Institute for Health and Welfare, competent authority for assessing whether research requires institutional ethical review or if the Finnish communicable diseases law and the law on the duties of the Finnish institute for Health and Welfare allows the implementation of the research without seeking further ethical review.The vaccinee cohort (n=20) was randomly selected from a larger cohort (n=180) of vaccinated healthcare personnel of Turku University Hospital [16] approved by the Southwest Finland health district ethical permission ETMK 19/1801/2020. Written informed consent was obtained from all volunteers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.